Market Overview

UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Related RNN
Rexahn Will Present Trial Results for Archexin at AACR
Rexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast Cancer

Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.

Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients."

Rexahn Pharmaceuticals closed at $0.29 on Thursday.

Latest Ratings for RNN

Mar 2015MLV & Co.Initiates Coverage onBuy
Sep 2014Laidlaw & Co.Initiates Coverage onBuy
Mar 2014Brinson PatrickInitiates Coverage onOutperform

View More Analyst Ratings for RNN
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (RNN)

View Comments and Join the Discussion!